All In Biotech

Drug Trial Radar · NCT05954988

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacodynamic Biomarker Study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Recently Diagnosed, Treatment Naïve Subjects With IPF

Last checked: Nov 19, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Jul 6, 2023

Primary completion

Sep 25, 2024

Study completion Sep 25, 2024

Sponsor

Lead sponsor
Rein TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • LTI-03Drug

    Caveolin-1-Scaffolding-Protein-Derived Peptide

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: 21 days (dosing x 14 days; follow up x 7 days)

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • University of Southern California

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Agaplesion Evangelisches Krankenhaus Mittelhessen

    Giessen, Germany

  • University of Edinburgh

    Edinburgh, United Kingdom

  • Royal Brompton Hospital

    London, United Kingdom

  • Royal Victoria Infirmary

    Newcastle, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.